SYNBIOTIC COMBINATION OF PROBIOTIC AND HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL MICROBIOTA

• US 20120171166A1
• Filed: 12/22/2011
• Published: 07/05/2012
• Est. Priority Date: 12/31/2010
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories
• Original Assignee: Abbott Laboratories
• Inventors: Chow, JoMay, Buck, Rachael
• Application Number:
  US13/335,341
• Publication Number:
  US 20120171166A1
• Time in Patent Office: Days
• US Class Current: 424/93.4
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2200/3202 Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A23V 2250/28 Oligosaccharides
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7016 Disaccharides, e.g. lactose, lactulose lactobionic acid A61K31/7032
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial microbiota. Suitable additional methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

Claims

1. A synthetic pediatric formula for promoting intestinal barrier integrity, the synthetic formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of a galactooligosaccharide, a fructooligosaccharide, and combinations thereof;

and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′

-fucosyllactose, 3′

-fucosyllactose, 3′

-sialyllactose, 6′

-sialyllactose, lacto-N-neotetraose, and combinations thereof.

2. The synthetic pediatric formula of claim 1, wherein the probiotic is of human infant origin.

3. The synthetic pediatric formula of claim 2, wherein the probiotic is a Bifidobacterium.

4. The synthetic pediatric formula of claim 3, wherein the probiotic is Bifidobacterium infantis.

5. The synthetic pediatric formula of claim 4, wherein the probiotic is selected from the group consisting of Bifidobacterium infantis M-63, Bifidobacterium infantis ATCC 15697, Bifidobacterium infantis 35624, Bifidobacterium infantis CHCC2228, Bifidobacterium infantis BB-02, Bifidobacterium infantis DSM20088, Bifidobacterium infantis R-0033, and combinations thereof.

6. The synthetic pediatric formula of claim 1, comprising probiotics in a concentration of from about 10³ CFU/g to about 10¹² CFU/g.

7. The synthetic pediatric formula of claim 1, comprising probiotics in a concentration of from about 10⁶ CFU/g to about 10⁷ CFU/g.

8. The synthetic pediatric formula of claim 1, further comprising at least one of a long chain polyunsaturated fatty acid, an antioxidant, a milk protein of human and/or bovine origin, vitamins, and minerals.

9. A method of promoting the growth of beneficial microbiota in the gastrointestinal tract of an infant or toddler in need thereof, the method comprising administering to the infant or toddler a synthetic pediatric formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of galactooligosaccharide, fructooligosaccharide, and combinations thereof;

and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′

-fucosyllactose, 3′

-fucosyllactose, 3′

-sialyllactose, 6′

-sialyllactose, lacto-N-neotetraose, and combinations thereof.

10. The method of claim 9, wherein the gastrointestinal diseases and/or disorders are selected from the group consisting of irritable bowel syndrome, colitis, food intolerance, and food allergies.

11. The method of claim 10, wherein the gastrointestinal disease is necrotizing enterocolitis.

12. The method of claim 9, wherein the probiotic is of human infant origin.

13. The method of claim 12, wherein the probiotic is a Bifidobacterium.

14. The method of claim 13, wherein the probiotic is Bifidobacterium infantis.

15. The method of claim 14, wherein the probiotic is selected from the group consisting of Bifidobacterium infantis M-63, Bifidobacterium infantis ATCC 15697, Bifidobacterium infantis 35624, Bifidobacterium infantis CHCC2228, Bifidobacterium infantis BB-02, Bifidobacterium infantis DSM20088, Bifidobacterium infantis R-0033, and combinations thereof.

16. The method of claim 9, wherein the synthetic pediatric formula comprises probiotics in a concentration of from about 10³ CFU/g to about 10¹² CFU/g.

17. The method of claim 9, wherein the synthetic pediatric formula comprises probiotics in a concentration of from about 10⁶ CFU/g to about 10⁷ CFU/g.

18. A method of stimulating enteric nerve cells in the gastrointestinal tract of an infant or toddler in need thereof, the method comprising administering to the infant or toddler a synthetic pediatric formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of galactooligosaccharide, fructooligosaccharide, and combinations thereof;

and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.05 mg/mL and selected from the group consisting of 2′

-fucosyllactose, 3′

-fucosyllactose, 3′

-sialyllactose, 6′

-sialyllactose, lacto-N-neotetraose, and combinations thereof.

19. The synthetic pediatric formula of claim 18, wherein the probiotic is of human infant origin.

20. The synthetic pediatric formula of claim 19, wherein the probiotic is a Bifidobacterium.